A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson's Disease. Protocol: ITI-214-202,
Role: Investigator,
Intra-Cellular Therapies, Inc,
(04/2024 - 04/2025)
Status: Approved
A Multicenter Phase 2, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants with Advanced Parkinson's Disease. PD0060,
Role: Investigator,
UCB Biopharma SPRL,
(03/2024 - 03/2025)
Status: Approved
A Phase I, Randomized, Open-Label, Active Controlled, Multi-Center Pilot Study to Compare Reference to Reference Pharmacodynamics of BOTOX® (onabotulinumtoxinA) in Healthy Subjects. Protocol: MR 103A-0I-IPS-1001. lnformed Consent Form Version Dated 25 November 2022.,
Role: Investigator,
Mylan Pharmaceuticals,
(11/2023 - 03/2024)
Status: Completed
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Repeat Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia. Protocol Number: ABP-19002,
Role: Investigator,
Aeon Biopharma,
(12/2022 - 12/2023)
Status: Completed
RESTORE: A clinical study of patients with symptomatic neuRogenic orthostatic hypotEnsion assess sustained effecTs of dRoxidopa therapy,
Role: Investigator,
Lundbeck Inc.,
(02/2022 - 02/2023)
Status: Completed
A phase 3, open-label study of the safety, efficacy, and tolerability of apomorphine administered by continuous subcutaneous infusion in advanced Parkinson's disease patients with unsatisfactory control on available therapy,
Role: PI,
U.S. World Meds,
(11/2021 - 11/2022)
Status: Completed
A Phase 3, open-label, multi-center trial to evaluate the long-term safety and efficacy of repeat treatment of DaxibotulinumtoxinA for injection in adult with isolated cervical dystonia (ASPEN-OLS). Protocol: 1720304,
Role: Investigator,
Revance Therapeutics, Inc.,
(04/2021 - 04/2022)
Status: Completed
A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multi-center trial to evaluate the efficacy and safety of a single treatment of DaxibotulinumtoxinA for injection in adults with isolated cervical dystonia (ASPEN-1). Protocol: 1720302,
Role: PI,
Revance Therapeutics, Inc.,
(11/2019 - 11/2020)
Status: Completed
Evaluation of the safety and pharmacodynamic effect of AGN-151607 by measuring the compound muscle action potential (CMAP) of the extensor digitorum brevis ( EDB) muscle following a single injection in healthy subjects. Protocol 1925-101-008, dated 18 August 2017. Informed consent form version dated 30 August 2017,
Role: Investigator,
Allergan Inc.,
(08/2018 - 08/2019)
Status: Completed
A 12-month, dose-level blinded study investigating the safety and efficacy of CVT-301 (Levodopa inhalation powder) in Parkinson's Disease patients with motor response fluctuations (off phenomena). protocol number: CVT-301-004E,
Role: Investigator,
Civitas Therapeutics, Inc.,
(03/2018 - 03/2019)
Status: Completed
ASPIRE: Adult spasticity international registry on BOTOX treatment,
Role: Investigator,
Allergan Inc.,
(10/2017 - 10/2018)
Status: Completed
A phase 3, multicenter, randomized, double-blinded, placebo controlled study with an open label phase to determine the efficacy and safety of tozadenant as adjunctive therapy in levodopa-treated patients with Parkinson's Disease experiencing end of dose "wearing off" (TOZ-PD). Protocol #: TOZ-CL05,
Role: Investigator,
Biotie Therapies Inc,
(07/2017 - 07/2018)
Status: Completed
A phase 3, long-term, open-label and single-arm study of MYOBLOC® in the treatment of troublesome sialorrhea in adult subjects. Protocol Number: SN-SIAL-351,
Role: Investigator,
U.S. World Meds,
(03/2017 - 03/2018)
Status: Completed
A phase 3, multi-center, double-blind, placebo-controlled, single-treatment efficacy and safety study of MYOBLOC® (Part A) followed by open-label, multiple-treatment with MYOBLOC® (Part B) in the treatment of troublesome Sialorrhea in adult subjects. Protocol number: SN-SIAL-301,
Role: Investigator,
U.S. World Meds,
(12/2016 - 12/2017)
Status: Completed
A phase 3, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of CVT-301 (Levodopa inhalation powder) in Parkinson's Disease patients with motor response fluctuations (OFF Phenomena). (SPAN-PD TM),
Role: Investigator,
Civitas Therapeutics, Inc.,
(12/2016 - 12/2017)
Status: Completed
An open-label, non-inferiority study evaluating the efficacy and safety of two injection schedules of xeomin (incobotulinumtoxinA) [short flex vs. long flex] in subjects with cervical Dystonia with < 10 weeks of benefit from onabotulinumtoxinA treatment. Protocol #MUS 60201 4073 1 dated 01Sep2011. Informed consent version dated 23Nov2011.,
Role: Investigator,
Merz Pharmaceuticals, LLC,
(01/2016 - 01/2017)
Status: Completed
A phase IIIb, prospective, multicentre, open-label extension study to assess long term safety and effectiveness of Dysport® using 2 mL dilution in adults with cervical dystonia. Protocol A-TL-52120-170,
Role: Investigator,
Ipsen Biopharmaceuticals, Inc.,
(03/2015 - 03/2016)
Status: Completed
A phase IIIb, multicentre, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of Dysport® using 2 mL dilution in adults with cervical dystonia. Protocol A-TL-52120-169,
Role: Investigator,
Ipsen Biopharmaceuticals, Inc.,
(03/2015 - 03/2016)
Status: Completed
A Multicenter, Interventional, Post-marketing, Randomized, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison with OnabotulinumtoxinA (Botox®) when Treating Adults with Upper Limb Spasticity. Protocol: CLIN-52120-452,
Role: Investigator,
Ipsen Pharma SAS,
(11/2024 - 11/2025)
Status: Approved
Internal
The development of oculomotor abnormalities in Parkinson's Disease,
Role: PI,
LLU Dept. of Neurology,
(12/2024 - 12/2025)
Status: Approved
MRI Evidence of Increased Iron Deposition in the Basal Ganglia of Patients Admitted for Stroke with a History of Methamphetamine Use: A Prevalence Study,
Role: PI,
LLU Dept. of Neurology,
(09/2023)
Status: Approved
Correlation of spirituality and Parkinson's disease,
Role: Investigator,
LLU Dept. of Neurology,
(05/2023)
Status: Approved
Access to Opicapone and Istradefylline in adult patients with Parkinson's disease,
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(10/2022)
Status: Approved
Evaluation of Risk Factors for Development of Drug-Induced Parkinsonism (DIP),
Role: Investigator,
LLU Dept. of Pharmacy Practice,
(10/2022)
Status: Approved
Does cannabis induce psychosis in Parkinson's disease patients?,
Role: PI,
LLU Dept. of Neurology,
(02/2019 - 09/2024)
Status: Completed
Non-Profit Organization
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability Of 24-Hour Daily Exposure of ABBV-951 in Subjects with Advanced Parkinson's Disease,
Role: Investigator,
AbbVie, Inc.,
(09/2024 - 09/2025)
Status: Approved
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX® for the Treatment of Upper Limb Essential Tremor. Protocol: M21-471,
Role: Investigator,
AbbVie, Inc.,
(09/2024 - 09/2025)
Status: Approved
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients.
Protocol: M15-736,
Role: Investigator,
AbbVie, Inc.,
(02/2021 - 02/2022)
Status: Completed